New drug targets genetic root of Parkinson's in key trial
NCT ID NCT06602193
Summary
This study is testing an investigational drug called BIIB122 in people with Parkinson's disease caused by specific genetic changes in the LRRK2 gene. About 50 participants will receive either the drug or a placebo for 12 weeks to see if it's safe and how it affects certain biological markers. The goal is to see if targeting this genetic pathway can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cedars-Sinai Department of Neurology
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Evergreen Health Laboratory
RECRUITINGKirkland, Washington, 98034, United States
Contact Email: •••••@•••••
Contact
-
Hospital Clinic de Barcelona
RECRUITINGBarcelona, Spain
Contact
Contact Email: •••••@•••••
-
Hospital Universitari General de Catalunya
RECRUITINGBarcelona, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, Spain
Contact Email: •••••@•••••
Contact
-
Hospital Universitario Donostia
RECRUITINGDonostia / San Sebastian, Spain
Contact Email: •••••@•••••
Contact
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, Spain
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
IDIVAL/University Hospital Marques de Valdecilla
RECRUITINGSantander, Spain
Contact
Contact Email: •••••@•••••
-
Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center
RECRUITINGNew York, New York, 10003, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Inland Northwest Research
RECRUITINGSpokane, Washington, 99202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Movement Disorders Institute, Sheba Medical Center
RECRUITINGRamat Gan, Israel
Contact Email: •••••@•••••
Contact
-
Parkinson's Disease and Movement Disorders Center
RECRUITINGBoca Raton, Florida, 33486, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rabin Medical Center
RECRUITINGPetah Tikva, Israel
Contact Email: •••••@•••••
Contact
-
Technische Universität Dresden
RECRUITINGDresden, Germany
Contact
Contact Email: •••••@•••••
-
Tel Aviv Medical Center
RECRUITINGTel Aviv, Israel
Contact Email: •••••@•••••
Contact
-
Universitary Hospital La Princesa
RECRUITINGMadrid, Spain
Contact
Contact Email: •••••@•••••
-
University Hospital Tübingen
RECRUITINGTübingen, Germany
Contact Email: •••••@•••••
Contact
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94158, United States
Contact Email: •••••@•••••
Contact
-
University of Lübeck
RECRUITINGLübeck, Germany
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.